Homology Medicines, Inc. (NasdaqGS: FIXX) Loss Submission Form

Kuznicki Law is investigating the proposed merger of Homology Medicines, Inc. (NasdaqGS: FIXX) with Q32 Bio Inc. Under the terms of the proposed transaction, Homology shareholders will end up owning approximately 25% of the combined company, subject to possible adjustment. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.